GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » Goodwill-to-Asset

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Goodwill-to-Asset : 0.00 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Skystar Bio-Pharmaceutical Co's Goodwill for the quarter that ended in Sep. 2014 was $0.00 Mil. Skystar Bio-Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2014 was $171.61 Mil. Therefore, Skystar Bio-Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Sep. 2014 was 0.00.


Skystar Bio-Pharmaceutical Co Goodwill-to-Asset Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co Goodwill-to-Asset Chart

Skystar Bio-Pharmaceutical Co Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Skystar Bio-Pharmaceutical Co Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset falls into.



Skystar Bio-Pharmaceutical Co Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Skystar Bio-Pharmaceutical Co's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

Goodwill to Asset (A: Dec. 2013 )=Goodwill/Total Assets
=0/136.223
=0.00

Skystar Bio-Pharmaceutical Co's Goodwill to Asset Ratio for the quarter that ended in Sep. 2014 is calculated as

Goodwill to Asset (Q: Sep. 2014 )=Goodwill/Total Assets
=0/171.608
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skystar Bio-Pharmaceutical Co  (GREY:SKBI) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Skystar Bio-Pharmaceutical Co Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN
Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines